Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.79 Consensus Target Price from Analysts

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average […]

Leave a Reply

Your email address will not be published.

Previous post FormFactor, Inc. (NASDAQ:FORM) Receives $48.50 Consensus PT from Analysts
Next post Match Group, Inc. (NASDAQ:MTCH) Receives $37.68 Average PT from Analysts